News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OX-MPI Project Returned To Orexo AB (ORXOF)


8/6/2014 9:57:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (publ) (STO:ORX) announces today that Boehringer Ingelheim has decided to return the OX-MPI project to Orexo. The project aims to develop products based on specific inhibition of prostaglandin E2 (PGE2) in different disease conditions. Boehringer Ingelheim has since 2005 been responsible for all research and development within the OX-MPI project.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Orexo AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES